2012 Fall Illustration Show
- Sep 1, 2012
- 1 min read
In the Fall of 2012, the illustration department at the Academy of Art, University threw its own seasonal show in Bradley Hall at the Illustration Building on Powell St. Sadly, they haven't done it again since, but luckily I was selected to show three pieces at this special event. My first time being selected for a show at AAU! So cool!
Genuinely impressed by the depth of this article!
Tirzepatide, the dual GIP/GLP-1 receptor agonist marketed as Mounjaro, has pushed the boundaries even further. Clinical trial data shows average weight reductions exceeding 20% of body weight in some cohorts, numbers that were previously only associated with bariatric surgery. This has sparked enormous interest in peptide therapy as a primary intervention for metabolic syndrome, not just as an adjunct. The conversation has shifted from 'can medication help with weight loss' to 'how do we best integrate these powerful incretin-based tools into comprehensive metabolic health programs.' Clinicians are now routinely discussing semaglutide dosing titration, injection technique, and long-term maintenance strategies as core components of obesity medicine.
The mechanism behind GLP-1 therapy is fascinating…